In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally ailment progression or perhaps the members are unable to tolerate the study drugs. There may be larger treatment load for individuals With this trial compared https://jamesn777zlv9.mywikiparty.com/user